Korean J Pancreas Biliary Tract.  2017 Jul;22(3):127-133. 10.15279/kpba.2017.22.3.127.

Effect of Capecitabine plus Oxaliplatin for Advanced Adenocarcinoma of Ampulla of Vater

• Lee JH
• Kim KH
• Woo SM
• Park SJ
• Han SS
• Hong EK
• Koh YH
• Lee JH
• Lee WJ

• KMID: 2448607
• DOI: http://doi.org/10.15279/kpba.2017.22.3.127

Abstract

BACKGROUND
/AIM: Adenocarcinoma arising from the ampulla of Vater is a rare disease and has limited data regarding outcome of palliative chemotherapy. We investigated the efficacy and safety of capecitabine plus oxaliplatin (XELOX) in patients with advanced ampullary adenocarcinoma.
METHODS
From October 2006 to January 2014, we retrospectively analyzed 28 patients with advanced ampullary adenocarcinoma treated by XELOX regimen at single institution. All the patients had histologically confirmed stage IV or recurrent ampullary adenocarcinoma. XELOX was administered in outpatient clinic every 3 weeks according to the following protocol: oral administration of capecitabine 750 mg/m² twice a day on days 1-14 and intravenous injection of oxaliplatin 130 mg/m² on day 1.
RESULTS
With follow-up of median 24.6 months (range 4.0-78.0 months), median progression-free survival (PFS) was 4.8 months (range 0.7-26.1 months), and median overall survival (OS) was 11.9 months (range 2.0-36.0 months). One patient (4%) achieved complete response and 5 patients (18%) showed partial response. There were no significant differences for PFS and OS according to response by chemotherapy. The most common grade 3 adverse events in patients were nausea and vomiting (10.7%). There was no treatment-related mortality.
CONCLUSIONS
XELOX regimen is well tolerated and show moderate activity against advanced ampullary adenocarcinoma.

Keyword

Adenocarcinoma; Ampulla of Vater; Capecitabine; Oxaliplatin; Antineoplastic agents

MeSH Terms

Adenocarcinoma*
Administration, Oral
Ambulatory Care Facilities
Ampulla of Vater*
Antineoplastic Agents
Capecitabine*
Disease-Free Survival
Drug Therapy
Follow-Up Studies
Humans
Injections, Intravenous
Mortality
Nausea
Rare Diseases
Retrospective Studies
Vomiting
Antineoplastic Agents
Capecitabine